CoChat

Special considerations for the diagnosis and treatment of invasive pulmonary aspergillosis

McCarthy, Matthew William, Walsh, Thomas J · 2017 · Expert Review of Respiratory Medicine

The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: The diagnosis and treatment of invasive pulmonary aspergillosis (IPA) are ongoing challenges in clinical practice. While important advances have recently been made, including enhanced diagnostic modalities as well as novel therapeutic and prophylactic options, more effective options are urgently needed as the population of immunocompromised patients continues to expand. Areas covered: In this paper, we review novel approaches to diagnosis of IPA, including multiplex PCR, Matrix Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry and provide a detailed review of the extended-spectrum triazole isavuconazole, which was approved in 2015 to treat IPA. Expert commentary: We explore burgeoning approaches to diagnosis, including the lateral flow assay, volatile organic compounds, and artificial olfactory technology, as well as novel antifungal agents to treat IPA such as SCY-078 and F901318.

Overview

Integrity signals

Registry

Crossref · 10.1080/17476348.2017.1340835

Cites

137 of 137 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 137 references

Research works printed but not linked: 14

  1. Jaumally BA, 2017, Respir Med Case Rep, 20, 156
  2. Agarwal R, 2016, Med Mycol, 87
  3. Fernandes L, 2016, J Clin Diagn Res, 10, OD16
  4. Machetti M, 2006, Infez Med, 14, 197
  5. Walsh TJ, 1998, Curr Clin Top Infect Dis, 18, 101
  6. Cruciani M, 2015, Cochrane Database Syst Rev, 10, CD009551
  7. Donnelley MA, 2016, Infect Drug Resist, 9, 79
  8. Desai A, 2016, Clin Pharmacol Drug Dev, 9, 291
  9. Law D, 2016, The efficacy of F901318 a novel antifungal drug in an animal model of aspergillosis
  10. Arthurs B, 2017, Respir Med Case Rep, 21, 27
  11. Er Dedekarginoglu B, 2017, Exp Clin Transplant, 15, 214
  12. Hollomon D, 2017, Pest Manag Sci, 12, 412
  13. Astvad KM, 2017, Clin Microbiol Infect, 32, 311
  14. 10.1128/AAC.02068-16 · DOI

Cited by

See all 8

Metadata

Authors
McCarthy, M. W., & Walsh, T. J.
Affiliations
  • Cornell University (US)
  • Weill Cornell Medical Center (US)
Corresponding author
McCarthy, Matthew William
Venue
Expert Review of Respiratory Medicine
Published
2017-06-21
Volume
11
Issue
9
Pages
739-748
ISSN
  • 1747-6348 (ISSN-L)
  • 1747-6356
OpenAlex
W2623020088
Cited by
8
References
137
Citations by year
2025: 1 · 2023: 1 · 2022: 4 · 2018: 1 · 2017: 1
FWCI
0.08
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Review of Respiratory Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
Keywords
invasive pulmonary aspergillosis, Aspergillus, immunocompromised patients, diagnostic methods, multiplex PCR, MALDI-TOF mass spectrometry, isavuconazole, triazoles, lateral flow assay, volatile organic compounds, antifungal agents, prophylaxis
MeSH terms
Antifungal Agents, Humans, Nitriles, Pyridines, Triazoles, Immunocompromised Host, Treatment Outcome, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Invasive Pulmonary Aspergillosis, Multiplex Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Special considerations for the diagnosis and treatment of invasive pulmonary aspergillosis. https://app.cochat.ai/papers/10.1080/17476348.2017.1340835
The paper
McCarthy, M. W., & Walsh, T. J. (2017). Special considerations for the diagnosis and treatment of invasive pulmonary aspergillosis. Expert Review of Respiratory Medicine. https://doi.org/10.1080/17476348.2017.1340835

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.